Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

Inge M. van der Sluis; Yves Bertrand; André Baruchel; Rob Pieters

doi:10.1111/bjh.18372

Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

Inge M. van der Sluis, Yves Bertrand, André Baruchel, Rob Pieters

Group Pieters

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

1 Citaat (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	e82-e83
Tijdschrift	British journal of haematology
Volume	198
Nummer van het tijdschrift	6
DOI's	https://doi.org/10.1111/bjh.18372
Status	Gepubliceerd - sep. 2022

Toegang tot document

10.1111/bjh.18372

Citeer dit

@article{295a54b25a7f4f689e5e92a1a9a37452,

title = "Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?",

keywords = "Antineoplastic Agents/therapeutic use, Asparaginase/therapeutic use, Erythrocytes, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy",

author = "\{van der Sluis\}, \{Inge M.\} and Yves Bertrand and Andr{\'e} Baruchel and Rob Pieters",

note = "Funding Information: All authors contributed to the writing.",

year = "2022",

month = sep,

doi = "10.1111/bjh.18372",

language = "English",

volume = "198",

pages = "e82--e83",

journal = "British journal of haematology",

issn = "0007-1048",